Safety lancet (XL)
Tianjin Huahong Technology Co., Ltd. · Decision date Sep 13, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-09-13 for K262526, a traditional 510(k) submitted by Tianjin Huahong Technology Co., Ltd. of Tianjin, CN. The device is listed as Safety lancet (XL), under the classification name Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature, regulation number 878.4850, product code FMK, in the General & Plastic Surgery specialty and review panel. The application was received 07/22/2026.
SESE indicates clearance to market as substantially equivalent to a predicate device; it is not premarket approval. The record shows the review was not conducted by a third party, the product is not a combination product, and no predetermined change control plan was authorized. The source does not identify the predicate device, the specific components or design changes assessed, or any clinical performance data, so those details remain unknown from this record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 13, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262526
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Tianjin Huahong Technology Co., Ltd.
- Product code
- FMK
- Decision code
- SESE
- Decision date
- Sep 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature.
- Applicant
- Tianjin Huahong Technology Co., Ltd.
- Product code
- FMK
- FDA device class
- 2
FDA decision timeline
K262526 received
Application receipt date recorded by FDA.
K262526 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Tianjin Huahong Technology Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Tianjin
Sources and methodology
- Original FDA record: K262526
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records